The antibody drug conjugates market is projected to grow at an annualized rate of over 20%

Albert Brando

- 03-Mar-2021

Roots Analysis has done a detailed report on Antibody Drug Conjugates Market, covering various important aspects of the industry and identifying key future growth opportunities.

To order this 600+ page report, which features 190+ figures and 280+ tables, please visit this Antibody Drug Conjugates Market (5th Edition), 2019-2030.

Key Market Insights

Eminent representatives from different biopharmaceutical companies confirm the sustained interest in ADC therapeutics, highlighting the technological innovation that is driving contemporary R&D initiatives
Presently, over 240 ADC therapy candidates are being evaluated in clinical / preclinical stages for treating a variety of solid tumors / hematologic cancers
The pipeline features product candidates that target a wide range of biological antigens and are equipped with different cytotoxic warheads; a number of companies are focused on developing novel drug conjugates
In order to gain a competitive edge in the market, ADC developers are actively exploring new biological targets, conducting clinical trials across different geographies to treat diverse disease indications
A number of eminent scientists from renowned universities, owing to their involvement in clinical development efforts, have emerged as key opinion leaders within this market
Over the years, more than 16,000 patents related to ADCs have been filed / granted across the world, indicative of the ongoing pace of R&D activity in this field of research
Several investors, having realized the opportunity within this upcoming segment of targeted cancer therapeutics industry, have invested over USD 5 billion, in the period between 2011 and 2019
The increasing interest in this field is also reflected in the partnership activity; deals inked in the recent past were mostly focused on licensing of products / technologies, involving both international and indigenous stakeholders
In the recent years, several developer companies have initiated clinical trials to evaluate the therapeutic potential of ADCs in combination with other drug / therapy classes
Anticipating the launch of several product candidates, stakeholders are exploring diverse commercialization strategies across different stages of the launch cycle along with the appropriate reimbursement strategies
Given the complexities associated with the development and production of ADCs, CMOs are indispensable to the R&D and manufacturing activity in this domain; some CMOs have even pioneered the novel ADC technology platforms
Case Study: In order to keep patients and healthcare professionals informed and aware of the developments, companies are deploying diverse promotional strategies for their respective products
With a promising development pipeline and encouraging clinical results, the global market is anticipated to witness growth at an annualized rate of over 20% during the next decade
The anticipated future opportunity is likely to be distributed across different types of Antibody Drug Conjugates Market (5th Edition), 2019-2030.ers and target antigens as more late-stage drugs get commercialized and existing marketing authorizations are expanded